文献速递母胎医学产科

羊膜腔穿刺诊断母体原发感染后的先天性巨细胞病毒感染

Amniocentesis to diagnose congenital cytomegalovirus infection following maternal primary infection.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-05-06

该研究为多中心随机安慰剂对照试验的二次分析,纳入2012至2018年397例妊娠24周前诊断原发巨细胞病毒感染孕妇,其中55例(14%)接受羊膜腔穿刺。羊膜腔穿刺诊断先天性巨细胞病毒感染的灵敏度为86%(95%CI 57-98),特异度100%(95%CI 91-100),阳性预测值100%(95%CI 74-100),阴性预测值95%(95%CI 83-99)。

要点

  • 羊膜腔穿刺诊断先天性巨细胞病毒感染的灵敏度86%、特异度100%。
  • 羊膜腔穿刺阳性者分娩孕周更早(37.4 vs 39.6周,P<.001),出生体重更低(2583±749 vs 3428±608 g,P=.004)。
  • 397例中仅55例(14%)接受羊膜腔穿刺,53例有巨细胞病毒结果,14例(25%)阳性。

核心结论

  • 羊膜腔穿刺结果是先天性巨细胞病毒感染的准确预测指标。

研究设计与样本

  • 多中心随机安慰剂对照试验的二次分析,该试验旨在评估巨细胞病毒超免疫球蛋白能否减少妊娠24周前诊断原发巨细胞病毒感染孕妇新生儿的先天性巨细胞病毒感染。
  • 2012至2018年共纳入397例受试者,随机分组时无胎儿感染的临床证据,随机接受每月巨细胞病毒超免疫球蛋白输注或安慰剂直至分娩。
  • 试验方案虽不要求,但允许随机分组后行羊膜腔穿刺;分娩时对胎儿和新生儿进行巨细胞病毒检测。

主要发现

  • 397例中55例(14%)接受羊膜腔穿刺,53例胎儿和新生儿有巨细胞病毒结果,14例羊膜腔穿刺阳性(25%)。
  • 胎儿或新生儿感染患病率为26%(14/53);12例羊膜腔穿刺阳性且有结果者新生儿分娩时均确认巨细胞病毒感染,41例羊膜腔穿刺阴性者中2例新生儿确认感染。
  • 羊膜腔穿刺诊断灵敏度86%(95%CI 57-98),特异度100%(95%CI 91-100),阳性预测值100%(95%CI 74-100),阴性预测值95%(95%CI 83-99)。
  • 羊膜腔穿刺阳性与阴性者相比,分娩孕周更早(37.4 vs 39.6周,P<.001),出生体重更低(2583±749 vs 3428±608 g,P=.004)。
  • 羊膜腔穿刺时孕周及母体诊断至羊膜腔穿刺间隔在巨细胞病毒存在与不存在者间相似。

关键数值与推荐

  • 羊膜腔穿刺诊断先天性巨细胞病毒感染的灵敏度86%(95%CI 57-98)、特异度100%(95%CI 91-100)、阳性预测值100%(95%CI 74-100)、阴性预测值95%(95%CI 83-99)。
  • 胎儿或新生儿感染患病率26%(14/53)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Congenital cytomegalovirus infection following maternal primary cytomegalovirus infection affects approximately 0.4% of newborns in the United States but may be hard to diagnose prenatally. OBJECTIVE: To evaluate the current sensitivity and specificity of amniocentesis in detecting congenital cytomegalovirus infection. STUDY DESIGN: Secondary analysis of a multicenter randomized placebo-controlled trial designed to evaluate whether cytomegalovirus hyperimmune globulin reduces congenital cytomegalovirus infection in neonates of individuals diagnosed with primary cytomegalovirus infection before 24 weeks of gestation. At randomization, subjects had no clinical evidence of fetal infection. Eligible subjects were randomized to monthly infusions of cytomegalovirus hyperimmune globulin or placebo until delivery. Although not required by the trial protocol, amniocentesis following randomization was permitted. The fetuses and neonates were tested for the presence of cytomegalovirus at delivery. Comparisons were made between those with and without amniocentesis and between those with cytomegalovirus-positive and negative results, using chi-square or Fisher exact test for categorical variables and the Wilcoxon rank sum test or t test for continuous variables. A P value of <.05 was considered significant. RESULTS: From 2012 to 2018, 397 subjects were included, of whom 55 (14%) underwent amniocentesis. Cytomegalovirus results were available for 53 fetuses and neonates. Fourteen amniocenteses were positive (25%). Gestational age at amniocentesis was similar between those with and without cytomegalovirus present, as was the interval between maternal diagnosis and amniocentesis. The prevalence of fetal or neonatal infection was 26% (14/53). The neonates of all 12 subjects with a positive amniocentesis and available results had cytomegalovirus infection confirmed at delivery, as did 2 neonates from the group of 41 subjects with a negative amniocentesis, with a sensitivity of 86% (95% confidence interval, 57-98), specificity of 100% (95% confidence interval, 91-100), positive predictive value of 100% (95% confidence interval, 74-100), and negative predictive value of 95% (95% confidence interval, 83-99). Amniocentesis-positive pregnancies were delivered at an earlier gestational age (37.4 vs 39.6 weeks; P<.001) and had lower birthweights (2583±749 vs 3428±608 g, P=.004) than amniocentesis-negative pregnancies. CONCLUSION: Amniocentesis results are an accurate predictor of congenital cytomegalovirus infection.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Dinsmoor MJ, Fette LM, Hughes BL, et al. Amniocentesis to diagnose congenital cytomegalovirus infection following maternal primary infection. Am J Obstet Gynecol MFM. 2022. PMID: 35526782. doi:10.1016/j.ajogmf.2022.100641

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。